(CercleFinance.com) – Stifel raises its recommendation on Sanofi from ‘hold’ to ‘buy’ with a price target raised from 95 to 109 euros, with an adjustment to the value of the pipeline in its model for the French health giant .
The broker says it is ‘reasonably optimistic that Sanofi can post a strong short-term growth cycle driven by Dupixent and Beyfortus (average annual EPS growth of 11% over 2024-27), followed by a realization phase of the improved pipeline’.
Copyright © 2024 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
